-
MFN Monitor: Europe’s Drug Launch Model Is Becoming a U.S. Pricing Risk
Written by
Traditional Global Launch Strategies Are Now Under Pressure For decades, the commercial path for innovative therapeutics followed a relatively predictable pathway. Secure FDA-approval, establish strategic pricing and a robust commercial footprint in US, and expand into Europe shortly thereafter. That framework has now come under attack due to the uncertainty related to the pricing policy debate between biopharma and the current US administration. The growing political and regulatory scrutiny surrounding Most Favored Nation (MFN) drug…
-
J.P. Morgan Healthcare Conference, the “Superbowl of Healthcare” – 2026 Watchlist
Written by
In December 2025, as we prepare for JP Morgan Healthcare on Jan 12-15, 2026, the U S Congress will be refining federal government funding of US Healthcare as influenced by the One Big Beautiful Bill Act (OBBBA). Spending on Medicare Part D drugs and overall Medicaid programs are once again in the cross hairs, and recent drug pricing and reimbursement reforms are likely to intensify in 2026. Prescription Drug Spending and Funding Trends According to…
